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Background: Long-acting muscarinic antagonists (LAMA), long-acting b2-agonists (LABA) and
fixed dose combinations (FDC) of inhaled corticosteroids (ICS) and LABA are used as inhaled
maintenance therapies for COPD.
Objective: To estimate persistence rates from dispensing patterns of long-acting inhaled drugs
for COPD.
Methods: From the PHARMO-database, COPD patients starting LAMA, LABA or LABA-ICS FDC
between 2002 and 2006 were selected. Persistence with the initial as well as with any long-
acting inhaled drug was determined, defined as time between start and stop of initial/any
therapy, allowing 60-days gaps between refills. For patients who did not continue to receive
dispensings of the initial therapy for at least one year, the first change in therapy was deter-
mined.
Results: The study included 2201 LAMA, 1201 LABA and 4146 LABA-ICS FDC users. Persistence rates
with initial therapy alone at 1, 2, and 3 years were 25%, 14%, 8% for LAMA, 21%, 10%, 6% for LABA
and 27%, 14%, 8% for LABA-ICS FDC. Of patients who did not persist with LAMA alone for one year,
15% added and 13% switched therapy (bothmostly LABA-ICS FDC). Of patients not persistingwith LABA
alone,9%addedtherapy (mostly LAMA)and31%switchedtherapy (mostly toLABA-ICSFDC). Inpatients
not persisting with LABA-ICS FDC, add-on and switch occurred equally frequent (11%, mostly LAMA).
Persistence rates with any long-acting drug at 1, 2 and 3 years were 36%, 23% and 17% respectively.
Conclusion: Persistencewith the initial aswell aswithany long-acting inhaleddrug inCOPD is low,with
a substantial proportion of patients changing therapy.
ª 2010 Elsevier Ltd. All rights reserved.2345 162; fax: þ31 302345 568.
armo.nl (F. Penning-van Beest).
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260 F. Penning-van Beest et al.Introduction well as with any long-acting inhaled drug for COPD in dailyAccording to the latest estimates of the World Health
Organisation (WHO), 210 million people have chronic
obstructive pulmonary disease (COPD) and 3 million people
died of COPD in 2005. The WHO predicts that COPD will
become the third leading cause of death worldwide by
2030.1
COPD cannot be cured, but pharmacological manage-
ment aims to provide symptom control, improve health
status and reduce exacerbations. Inhaled bronchodilators
are key therapies in the management of COPD.2 Short-
acting bronchodilators increase exercise tolerance acutely
and are often used as ‘rescue’ medication. Guidelines such
as those produced by the Global Initiative for Chronic
Obstructive Lung Disease (GOLD)2 recommend long-acting
bronchodilators (either alone or in combination) as main-
tenance therapy in patients with moderate or severe
disease (with moderate defined as an FEV1/FVC ratio of
<0.70 and percent predicted FEV1 between 50 and 80%;
and severe disease as FEV1/FVC <0.70 and predicted FEV1
between 30 and 50%). Such patients should also have access
to pulmonary rehabilitation which offers a number of
benefits and covers a range of non-pulmonary problems
that may not be adequately addressed by medical therapy
such as exercise de-conditioning. In the Netherlands, the
long-acting b2-agonists (LABA) salmeterol and formoterol
and the long-acting muscarinic antagonist (LAMA) tio-
tropium are available. Inhaled corticosteroids (ICS) are
recommended in the GOLD guidelines as add-on therapy in
the management of severe COPD patients with repeated
exacerbations.2 Fixed dose combinations (FDC) of LABA and
ICS are available in the Netherlands as salmeterol-flutica-
sone propionate and formoterol-budesonide.
Since COPD is a chronic and progressive disease, the use
of long-acting inhaled drugs is expected to be long-term.
Adherence, however, is often problematic as a result of
periods of symptom remission, the complexity of treatment
regimens and administration, patients’ perceptions of their
illness and their understanding of the treatment.3 More-
over, clinical efficacy of inhaled therapy is not always
obvious for each patient. In addition, poor adherence to
COPD management guidelines by physicians has been
demonstrated.3e5 It should be noted that adherence
encompasses both compliance and persistence and this
study only considers the latter. Studies from daily practice,
including an earlier PHARMO study, have shown that
persistence with long-acting inhaled drugs is low. Breek-
veldt-Postma et al. found that only 37% of new users of
tiotropium, 13% of new LABA users and 17% of new LABA-ICS
FDC users continued using this drug for at least one year.6 In
the study by Cramer et al. only 12e27% of patients starting
on LAMA, LABA, or LABA-ICS FDC continued on the initial
drug for more than one year.7 As the aim of these studies
was to compare different COPD drugs, persistence was
restricted to the initial drug. Since patients with COPD
cannot be cured and guidelines suggest either adding or
changing therapy as the disease worsens, a better reflec-
tion of persistence with long-acting inhaled drug treatment
is obtained when persistence is determined irrespective of
the specific drug type. Therefore, the aim of our study was
to determine persistence rates with the initial therapy aspractice up to three years after start. Moreover, changes in
treatment during the first year of therapy were studied.
Methods
Setting
Data were obtained from the PHARMO medical record
linkage system (PHARMO RLS), a population-based patient-
centric data tracking system including high quality and
complete information linked on a patient level of, among
other things, patient demographics, drug dispensings and
hospital morbidity of approximately 3 million community-
dwelling inhabitants of 48 geo-demographic areas in the
Netherlands. The drug dispensing histories contain data on
the dispensed drug, the prescriber, the dispensing date, the
amount dispensed, the prescribed dose regimens, and thus
the duration of use. All drugs are coded according to the
Anatomical Therapeutic Chemical (ATC) Classification. The
hospital records include detailed information concerning
the primary and secondary diagnoses, procedures, and
dates of hospital admission and discharge.
Study patients
From the PHARMO RLS, we first identified all new, probable
COPD patients in the period of 2001e2006. New, probable
COPD patients were identified as patients with a first
dispensing for COPD therapy in the period of 2001e2006
(i.e. the index date) at the age of 55 or older, including:
short-acting b2-agonists (SABA), LABA, short-acting
muscarinic antagonists (SAMA), LAMA, LABA-ICS FDC, SABA-
SAMA FDC, and xanthine derivatives. To ensure that COPD
therapy was started at the age of 55 or above and to
enhance the probability that a patient was treated for
COPD instead of for asthma, patients had to have a regis-
tration in PHARMO RLS of at least two years before the
index date and no dispensing for any drug for obstructive
airway diseases or nasal corticosteroids in these years.
Additionally, patients with a hospitalisation for asthma in
the period of 1999e2007 were excluded from the COPD
cohort. Moreover, patients were excluded if they were
hospitalised for lung cancer, lung surgery, tuberculosis,
sarcoidosis, lung fibrosis or pneumoconiosis in this period
as these diseases can also demonstrate COPD-like
symptoms.
From the COPD cohort, new users of LAMA, LABA or
LABA-ICS FDC in the period 2002e2006, i.e. no use of these
long-acting COPD drugs in 2001, were included in the study
cohort. The date of the first dispensing for LAMA, LABA or
LABA-ICS FDC was defined as study entry date. New users
were only included if they had at least a second dispensing
for any of the long-acting inhaled drugs within 180 days
after study entry, started on monotherapy, i.e. LAMA only,
LABA only or LABA-ICS FDC only, and had at least three
years of follow-up after study entry. End of follow-up was
the date of death, end of data collection (e.g. because the
patient moved outside the PHARMO catchment area) or
end of study period (31 December 2007), whichever came
first.
Persistence with long-acting inhaled drugs in COPD 261Persistence
For each study patient, all dispensings for LAMA, LABA and
LABA-ICS FDC during the three-year follow-up period were
converted into treatment episodes of continuous use of
respectively LAMA, LABA and LABA-ICS FDC, based on the
method of Catalan.8 A treatment episode was considered
uninterrupted if the gap between dispensings was 60 days
or less, as done by Cramer et al.7 Otherwise, use of the drug
class was considered interrupted, the respective treatment
episode was ended and a next episode defined.
Persistence with the initial long-acting inhaled mono-
therapy, i.e. the number of days of continuous use
including permissible gaps of maximally 60 days, was
determined as the number of days from the start of this
therapy (i.e. study entry date) to the end date of the first
treatment episode or the start date of a dispensing of one
of the other two long-acting inhaled drug classes, which-
ever occurred first. In addition to the persistence with the
initial long-acting inhaled monotherapy, we also assessed
the persistence with any long-acting inhaled drug, i.e. the
number of days of continuous use of any long-acting inhaled
drug from study entry date onwards including permissible
gaps of maximally 60 days. In this analysis, all dispensings
for LAMA, LABA and LABA-ICS FDC during follow-up were
converted into treatment episodes of continuous use of any
long-acting inhaled drug.
Treatment pattern
For study patients who did not persist with the initial
monotherapy for at least one year, i.e. the number of days
of continuous use including permissible gaps was less than
365, we determined whether they: 1) had switched to one
of the other two long-acting inhaled drug classes, or 2) had
an add-on of the other two long-acting inhaled drug classes,
or 3) had no switch or add-on and restarted the initial drug
class within 60 days, i.e. a second treatment episode of the
initial drug class was started within 60 days after the end
date of the first treatment episode, or 4) had no switch or
add-on and stopped using the initial drug class for at least
60 days.
Switching was defined as starting one of the other two
long-acting inhaled drug classes after the last dispensing
within the first treatment episode of the initial drug class or
within 60 days after the end of that episode. An add-on was
defined as 1) starting one of the other two long-acting
inhaled drug classes before the last dispensing within the
first treatment episode of the initial drug class, or 2)
starting one of the other two long-acting inhaled drug
classes within 60 days after the end date of the first
treatment episode of the initial drug class and restarting
the initial drug at this date.
User type
In addition to the above mentioned dichotomous outcome
‘persistent with any long-acting inhaled drug’, study
patients who were not classified as persistent for at least
three years were further analysed to characterise the usage
pattern of long-acting inhaled drugs in this expectedly largepatient group. The following user types, based on all long-
acting inhaled drug dispensings within three years of
follow-up, were distinguished:
 regular users: patients with at least one discontinuation
of their long-acting treatment for a period of 61 days of
more, but no longer than 180 days;
 inconsistent users: patients with at least one discon-
tinuation of their long-acting treatment for more than
180 days;
 short-term users: patients with dispensings for long-
acting inhaled drugs in the first year only.
For these different types of users we determined their
co-medication use during follow-up including oral cortico-
steroids, oral antibiotics and respiratory drugs besides long-
acting drugs. This information on co-medications may help
explain a patient’s usage pattern of long-acting COPD
drugs.
Analyses
All data were analyzed using SAS programs organised within
SAS Enterprise Guide version 3.0 (SAS Institute Inc., Cary,
NC, USA) and conducted under UNIX using SAS version 9.1.
Persistence with treatment over time was analysed using
Kaplan Meier survival analyses. As the study only included
patients with at least three years of follow-up, persistence
results may not be representative for all COPD patients.
Therefore, a sensitivity analysis for one- and two year
persistence with the initial monotherapy was performed
including patients with at least one and two years of follow-
up respectively (instead of the required three years).
Similarly, changes in treatment were also determined in
non-persistent patients with at least one year of follow-up.
Rates of persistence with any long-acting inhaled drug after
one, two and three years were determined separately for
a subset of patients with a hospitalisation with a primary or
secondary discharge diagnosis of COPD in their entire
available history and follow-up in the PHARMO RLS. This
sub-analysis was performed because selecting patients
based on their drug use, as opposed to diagnoses which
were not available in the dataset, means that we could not
rule out that patients treated for diseases other than COPD
were included in the study cohort. The subset of patients
with a primary or secondary discharge diagnosis of COPD
are most likely to have the disease. Please note, as
mentioned above, this hospitalisation may have occurred
before or after study entry and even after end of study
follow-up. Furthermore, COPD was not necessarily the
primary reason for hospitalisation.
Results
The COPD cohort included 54,807 patients. Of these, 28,462
patients (52%) were new users of LAMA, LABA or LABA-ICS
FDC in the period 2002e2006; 17,371 patients had at least
a second dispensing for any of the long-acting inhaled drugs
within 180 days and 15,668 patients also started on mono-
therapy. The final study cohort included 7548 patients with
at least three years of follow-up after study entry, i.e. 2201
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and 4146 patients starting on LABA-ICS FDC. The use of
these long-acting inhaled drugs was mostly initiated by
a general practitioner (71e80% of patients, Table 1). In the
year before start of LAMA, LABA or LABA-ICS FDC use,
30e52% of patients had used some other respiratory drug,
21e28% had used oral corticosteroids and 53e60% had used
oral antibiotics. Co-morbidity was frequent among study
patients: about 60% of patients had used drugs from at least
four different drug classes (besides respiratory drugs) in the
year before study entry.
Fig. 1 shows the proportion of patients who were still
using the initial long-acting inhaled monotherapy over
time. Persistence rates at 1, 2, and 3 years were 25%, 14%
and 8% for LAMA, 21%, 10% and 6% for LABA and 27%, 14%Table 1 Characteristics of COPD patients starting use of long-a
Patients starting on
LAMA N Z 2201 n (%)
Gender
Men 1193 (54.2)
Women 1008 (45.8)
Age group (in years)
55e64 574 (26.1)
65e74 786 (35.7)
75 841 (38.2)
Prescriber
General practitioner 1752 (79.6)
Pulmonologist 365 (16.6)
Other specialist 84 (3.8)
Use of other respiratory drugsa
Any drug 663 (30.1)
SAMA 319 (14.5)
SABA 235 (10.7)
SABA-SAMA FDC 71 (3.2)
ICS 217 (9.9)
Xanthine derivatives 11 (0.5)
Leukotriene receptor antagonists 2 (0.1)
Use of co-medication related to COPDa
Coughing agents 328 (14.9)
Mucolytics 237 (10.8)
Nasal preparations 135 (6.1)
Oral corticosteroids 455 (20.7)
Oral antibiotics 1236 (56.2)
Hospitalisation for COPDb 29 (1.3)
Co-morbiditya
Number of different drug classes used besides respiratory drugs
0e1 classes 207 (9.4)
2e3 classes 596 (27.1)
4e5 classes 776 (35.3)
6 classes 622 (28.3)
LAMA, long-acting muscarinic antagonists; LABA, long-acting b2-agon
SAMA, short-acting muscarinic antagonists; SABA, short-acting b2-ago
a Determined in the year before study entry date.
b Determined in the period from 1996 until study entry date.and 8% for LABA-ICS FDC. Similar one- and two-year rates
were observed in patients with at least one and two years
of follow-up respectively (data not shown).
Of patients who did not persist with LAMA alone for at
least one year (n Z 1643), 15% added and 13% switched
therapy (Table 2). The most frequently added long-acting
inhaled drug class was LABA-ICS FDC,whichwas also the drug
class patients most frequently switched to (70% of 240 add-
ons and 74% of 206 switches). Of patients not persisting with
LABA alone for one year (n Z 947), 9% added therapy and
31% switched therapy. The most frequent add-on was LAMA
(80% of 83 add-ons) and switches were mostly to LABA-ICS
FDC (78% of 296 switches). In patients not persisting with
LABA-ICS FDC alone (nZ 3027), add-on and switch occurred
with equal frequency (11%) and was mostly LAMA (92% of 335cting inhaled monotherapy.
Patients starting on
LABA N Z 1201 n (%)
Patients starting on
LABA-ICS FDC
N Z 4146 n (%)
560 (46.6) 1980 (47.8)
641 (53.4) 2166 (52.2)
382 (31.8) 1547 (37.3)
428 (35.6) 1482 (35.7)
391 (32.6) 1117 (26.9)
913 (76.0) 2958 (71.3)
214 (17.8) 1026 (24.7)
74 (6.2) 162 (3.9)
626 (52.1) 1500 (36.2)
264 (22.0) 503 (12.1)
234 (19.5) 918 (22.1)
62 (5.2) 205 (4.9)
339 (28.2) 357 (8.6)
28 (2.3) 38 (0.9)
3 (0.2) 16 (0.4)
177 (14.7) 748 (18.0)
132 (11.0) 408 (9.8)
61 (5.1) 270 (6.5)
335 (27.9) 1064 (25.7)
635 (52.9) 2485 (59.9)
39 (3.2) 68 (1.6)
133 (11.1) 445 (10.7)
336 (28.0) 1116 (26.9)
404 (33.6) 1401 (33.8)
328 (27.3) 1184 (28.6)
ists; FDC, fixed dose combinations; ICS, inhaled corticosteroids;
nists.
Figure 1 Kaplan Meier survival curve showing proportion of
persistent users up to three years after start per type of initial
long-acting inhaled monotherapy.
Persistence with long-acting inhaled drugs in COPD 263add-ons and 60% of 315 switches). Similar changes in treat-
ment were observed in non-persistent patients with at least
one year of follow-up (data not shown).
Including therapy changes, persistence rates with any
long-acting inhaled drug at 1, 2 and 3 years after start were
36%, 23% and 17% respectively. For a subset of patients with
a primary or secondary discharge diagnosis of COPD in their
entire available history and follow-up (nZ 903) these rates
were 50%, 33% and 26%.
Classification of study patients based on treatment
episodes of continuous use of any long-acting inhaled drug
within three years of follow-up, resulted in 21% regular
users, 34% inconsistent users and 28% short-term users (in
addition to 17% persistent users as mentioned above). Table
3 shows the co-medication use for these different types of
users. Short-term users had the lowest proportion of
patients using oral corticosteroids or oral antibiotics (30%
compared to 43e50% for corticosteroids, and 69% compared
to 76e79% for antibiotics). Similarly, respiratory drugs
besides long-acting drugs were less frequently used among
short-term users (34% compared to 46e54%).Discussion
In this population-based cohort study among COPD
patients starting use of LAMA, LABA or LABA-ICS FDC, only
21e27% of patients were still receiving dispensings of
their initial monotherapy after one year. Of patients who
did not appear to continue with the initial monotherapy,Table 2 First therapy change of COPD patients who were non
after one year of follow-up.
Initial drug non-persistent patients, N First therap
add-on, n (
LAMA 1643 240 (14.6)
LABA 947 83 (8.8)
LABA-ICS FDC 3027 335 (11.1)20e40% changed therapy (either add-on or switch).
Including therapy changes, one year persistence with any
long-acting inhaled drug was still only 36%. Two and three
years after start these rates were 23% and 17%,
respectively.
Selection of COPD patients for the current study was
based on respiratory drug use, as also done by de Melo
et al.9 and in the previous PHARMO study.6 By applying
exclusion criteria, such as age <55 years at onset of
respiratory drug use, prior use of asthma-specific drugs, and
asthma hospitalisation, as many asthma patients as possible
were excluded. Furthermore, patients with COPD-like
symptoms because of e.g. lung cancer or lung fibrosis were
excluded based on hospitalisations. However, we could not
rule out that some patients treated for diseases other than
COPD are included in the study cohort, e.g. patients who
developed or re-developed asthma late in life. No infor-
mation on smoking history, which would have helped
confirm a diagnosis of COPD, was available. Therefore, we
performed a sub-analysis in 903 patients with a hospital-
isation with a primary or secondary discharge diagnosis of
COPD in their entire available history and follow-up in
PHARMO RLS. Although persistence was higher in this subset
of certain COPD patients, rates were still low; only 50%, 33%
and 26% of patients were still using any long-acting inhaled
drug after 1, 2 and 3 years.
Long-acting bronchodilators are recommended when
patients continue to experience symptoms on short-acting
drugs. However, only one-third of our study patients had
used SAMA, SABA or SABA-SAMA FDC in the year before start
of LAMA, LABA or LABA-ICS FDC use. A post-hoc analysis
revealed that in this subset of patients persistence was also
low: 45%, 30% and 22% of patients were still using any long-
acting inhaled drug at 1, 2 and 3 years after start.
Persistence was based on permissible gaps between
dispensings of 60 days or less. Using a larger gap would have
yielded higher persistence rates. A post-hoc analysis
revealed that even when allowing 90-day gaps only 47% of
patients were still using any long-acting inhaled drug after
one year. Two and three years after start these rates were
31% and 24%, respectively.
To our knowledge, this is one of the first daily practice-
based studies on persistence with any long-acting inhaled
COPD drug. Available information in the literature is
restricted to persistence with the initial long-acting inhaled
COPD drug.6,7 The proportions of new LABA and LABA-ICS
FDC users still using this monotherapy after one year as
observed in our study (i.e. 21% and 27%) are slightly higher
than reported by Breekveldt-Postma et al. (13% and 17%,6)
and Cramer et al. (around 16% and 12%,7). However, we
only included patients with at least a second dispensing for-persistent with the initial long-acting inhaled monotherapy
y change
%) switch, n (%) restart, n (%) stop, n (%)
206 (12.5) 223 (13.6) 974 (59.3)
296 (31.3) 194 (20.5) 374 (39.5)
315 (10.4) 873 (28.8) 1504 (49.7)
Table 3 Use of oral corticosteroids, oral antibiotics and respiratory drugs besides long-acting drugs within three years of
follow-up stratified by type of user of long-acting drugs.
Type of user of long-acting drugs
Short-term users
N Z 2110, n (%)
Inconsistent users
N Z 2567, n (%)
Regular users
N Z 1612, n (%)
Persistent users
N Z 1259, n (%)
Oral corticosteroids 638 (30.2) 1099 (42.8) 756 (46.9) 627 (49.8)
Oral antibiotics 1461 (69.2) 2025 (78.9) 1235 (76.6) 950 (75.5)
Respiratory drugs besides long-acting drugs
Any drug 718 (34.0) 1169 (45.5) 846 (52.5) 680 (54.0)
SAMA 240 (11.4) 354 (13.8) 292 (18.1) 236 (18.7)
SABA 306 (14.5) 593 (23.1) 417 (25.9) 341 (27.1)
SABA-SAMA FDC 88 (4.2) 158 (6.2) 119 (7.4) 96 (7.6)
ICS 293 (13.9) 458 (17.8) 308 (19.1) 255 (20.3)
Xanthine derivatives 26 (1.2) 44 (1.7) 51 (3.2) 45 (3.6)
Leukotriene receptor antagonists 15 (0.7) 76 (3.0) 54 (3.3) 26 (2.1)
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study entry. Furthermore, study periods, patients’ age and/
or persistence measurements differed. Our one-year
persistence rate for LAMA alone (i.e. 25%) was similar to
Cramer’s rate (27%) but lower than found by Breekveldt-
Postma et al. (37%). The latter high persistence rate is
likely to be the result of tiotropium being prescribed to
a selected group of patients shortly after its market intro-
duction. Compared to our study patients, study patients
from Breekveldt-Postma et al. more often received their
first prescription from a pulmonologist, had a hospital-
isation for COPD in the year prior to start of tiotropium use
and used co-medication related to COPD. These factors
may be indicative of a higher disease severity, which has
been shown to be associated with increased persistence.10
In addition to the above mentioned persistence studies,
there are studies on refill adherence and medication
possession ratios, including long- as well as short-acting
inhaled drugs.11,12 Furthermore, studies specifically
focusing on persistence with ICS have been performed.10,13
These studies all also show that adherence to asthma/COPD
drugs in general is low.
A major strength of our study is that we estimated
persistence with the initial therapy as well as with any long-
acting inhaled drug for COPD. Furthermore, in addition to the
dichotomous outcome ‘persistent’, study patients were
classified into four user types based on their pattern of use of
long-acting inhaled drugs within three years of follow-up.
This analysis showed that 55% of patients, although not
persistent for three years, resumed long-acting drug use
after a gap of at least 61 days (i.e. the 4179 regular and
inconsistent users). This may indicate that symptom control
was insufficient without using long-acting drugs or be related
to seasonal or infrequent symptoms. A post-hoc analysis
revealed that the majority of these patients most likely had
not used any respiratory drugs during the gap in long-acting
drug use: only 39% of patients had a dispensing of other
respiratory drugs in the 90 days before or after the stop date.
From the user type classification we also know that 28%
of patients only had long-acting inhaled drug dispensings in
the first year after start (i.e. the 2110 short-term users).
Based on the information on use of SAMA, SABA, SABA-SAMAFDC, ICS, xanthine derivatives, leukotriene receptor
antagonists, oral corticosteroids and oral antibiotics within
three years of follow-up, these patients seem to have had
less severe disease and may have had sufficient symptom
control on short-acting drugs only. However, from the post-
hoc analysis we know that among short-term users only 27%
had a dispensing of other respiratory drugs in the 90 days
before or after the stop date.
Poor adherence to treatment in daily practice is likely
to limit optimal disease management, as shown for e.g.
antihypertensives, antidiabetics, statins and bispho-
sphonates.14e17 Future studies from daily practice should
determine the impact of poor persistence with COPD drugs
on patients’ outcomes such as lung function and rate of
exacerbations. In such a study accurate information on
severity of COPD is necessary as this is likely to be asso-
ciated with persistence as well as with the patient’s
outcome; low persisters may be the mild COPD patients
who have better short-term outcomes.
To improve persistencewith long-acting inhaled drugs, an
understanding of (patients’) reasons to (temporarily) stop
the use of these drugs is critical. Reasons for poor persistence
mentioned by patients in a questionnaire study included
difficulty in handling the inhaler, confusion about the
medications, or simply because the patient was feeling
good.3,18 With this information health professionals can
undertake activities to help their patients receive the most
appropriate treatment and continue taking it. In addition,
via targeted information and continuing-educationmeasures
the medical care of COPD patients may be improved.3e5
In conclusion, this analysis of dispensings indicates that
persistence with the initial long-acting inhaled drug in COPD
is low, with a substantial proportion of patients changing
therapy. Even when those who switch or add-on therapy are
considered persistent, rates remain low. Whether these
changes in dispensing patterns are physician-instigated or
patient-driven cannot be determined from these data.
Neither do we know the factors driving the changes e.g. poor
efficacy, adverse events, dosing regimen, device accept-
ability etc. However, the fact that persistence is low indi-
cates that the currently available first-line maintenance
treatmentsmaynot beadequate and/or thatmanagement of
Persistence with long-acting inhaled drugs in COPD 265patients is suboptimal. Future research shoulddetermine the
factors impacting on persistence and the impact of poor
persistence with COPD drugs on symptom relief and clinical
outcomes.
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